Calcified Tissue International

, Volume 49, Issue 6, pp 436–437 | Cite as

Cellular immunodeficiency in Paget's disease of bone: Changes induced by treatment with elcatonin

  • A. Rapado
  • M. Yague
  • M. Diaz Curiel
  • F. Ortiz
  • P. Palomino
  • C. de la Piedra
  • R. Torres
  • B. Peramo
  • E. Lopez Gavilanes
Rapid Communications
Received:
Accepted:

Summary

We have found a cellular immune defect (low CD4 T lymphocyte count, high CD8 T lymphocyte count and a low CD4/CD8 ratio) in 39 PDB patients. This finding is not correlated with the bone metabolic activity of the disease. There was an improvement in the cellular immune defect in fifteen patients after treatment with elcatonin. These changes could be related to the improvement in the metabolic derangement or else could be the consequence of an effect on altered immunity.

Key words

Paget's disease of bone CD4 counts CD4/CD8 ratio cellular immuno-deficiency elcatonin 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Mills BG, Singer FR (1987) Critical evaluation of viral antigen data in Paget's disease of bone. Clin Orthop 217:16–25PubMedGoogle Scholar
  2. 2.
    Kukita A, Chenu C, Mcmanus LM, Mundy GR, Roodman GD (1990) Atypical multinucleated cells form in long-term marrow cultures from patients with Paget's disease. J Clin Invest 85:1280–1286PubMedGoogle Scholar
  3. 3.
    Torres R., C. de la Piedra y A. Rapado (1989) Osteocalcin and bone remodelling in Paget's disease of bone, primary hyperparathyroidism, hypercalcemia of malignancy and involutional osteoporosis. Scand J Clin Lab Invest 49:279–285PubMedGoogle Scholar
  4. 4.
    Loken MR, Stout RD, Herzenberg LA (1978) Lymphoid cell analysis and sorting. In: Flow cytometry and sorting. Melamed MR et al (ed). 28. John Wiley and Sons. New YorkGoogle Scholar
  5. 5.
    De la Piedra C, Torres R, Rapado A et al. (1989) Serum tartrate-resistant acid phosphatase and bone mineral content in postmenopausal osteoporosis. Calcif Tissue Int 41:58–60CrossRefGoogle Scholar
  6. 6.
    Barker DJP (1984) The epidemiology of Paget's disease of bone: Br Med Bull 40:396–400PubMedGoogle Scholar
  7. 7.
    Morales A, Lopez Abente G, Elena A et al. (1988) Risk factors for Paget's disease: A new hypothesis. Int J Epidemiol 17:198–201CrossRefGoogle Scholar
  8. 8.
    Fotin M, Haymovits A, Folk CT (1977) Evidence for linkage between HLA and Paget's disease. Transplant Proc 9:1867–1868Google Scholar
  9. 9.
    Buxbaum JN, Kammerman S (1984) Immunoglobulin abnormalities in Paget's disease of bone. Clin Exp Immunol 55:200–204Google Scholar
  10. 10.
    Basle MF, Fournier JG, Rozenblatt S et al. (1986) Measles virus RNA detected in Paget's disease bone tissue by in situ hybridization. J Gen Virol 67:907–913PubMedCrossRefGoogle Scholar
  11. 11.
    Adami S, Suppi R, Residori M, et al. (1988) Intramuscular administration of salmon calcitonin impairs delayed cutaneous hypersensitivity. Bone Miner 4:91–94PubMedGoogle Scholar
  12. 12.
    Bijvoet OLM, Vellenga CJLR, Harinck HJJ (1989) Paget's disease of bones: Assessment, therapy and secondary prevention. In: Clinical disorders of bone and mineral metabolism. M. Kleerekoper and S. M. Krane (ed). Mary Ann Liebert. Inc. New York, 525–542Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • A. Rapado
    • 1
  • M. Yague
    • 1
  • M. Diaz Curiel
    • 1
  • F. Ortiz
    • 1
  • P. Palomino
    • 2
  • C. de la Piedra
    • 1
  • R. Torres
    • 1
  • B. Peramo
    • 1
  • E. Lopez Gavilanes
    • 1
  1. 1.Service of Internal Medicine (Unidad Metabólica)Fundación Jiménez Diaz and Universidad AutónomaMadridSpain
  2. 2.Service of ImmunologyFundación Jiménez Diaz and Universidad AutónomaMadridSpain

Personalised recommendations